When is Clinical Post-Market Surveillance Required for Software?

Introduction to Clinical Post-Market Surveillance

Clinical post-market surveillance is an important part of the lifecycle of software classified as a medical device. It is conducted to ensure the safety and effectiveness of the software after its market launch. Particularly for software used in medical care, it is crucial to identify and minimize potential risks.

When is Clinical Post-Market Surveillance Required?

Clinical post-market surveillance is required when the software is classified as a medical device. This is the case when the software:

• is used for the diagnosis, treatment, or monitoring of patients,
• poses potential risks to the health or safety of patients or users,
• undergoes changes or updates that could affect its performance or safety.

The necessity for clinical post-market surveillance may also depend on the risk class of the medical device. Higher-classified products typically require more extensive surveillance measures.

Objectives of Clinical Post-Market Surveillance

Clinical post-market surveillance has several objectives:

• Safety Monitoring: Identification and assessment of adverse events or side effects that may occur in connection with the software.
• Effectiveness Assessment: Verification that the software achieves the intended outcomes in clinical use.
• Data Analysis: Collection and evaluation of data to ensure long-term safety and effectiveness.

Conclusion

Clinical post-market surveillance is an essential process for software classified as a medical device. It ensures that the software remains safe and effective even after market launch. The exact requirements and procedures may vary depending on the specific classification and applicable regulatory requirements.